- Home
- NDMO vs CRMD Comparison
NDMO vs CRMD Comparison
Compare NDMO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDMO | CRMD |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.4M | 943.9M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NDMO | CRMD |
|---|---|---|
| Price | $9.98 | $12.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 218.6K | ★ 2.6M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 6.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | N/A | ★ $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | ★ N/A | $5.56 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $8.99 | $5.60 |
| 52 Week High | $11.24 | $17.43 |
Technical Indicators
Market Signals| Indicator | NDMO | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 28.12 | 66.86 |
| Support Level | $9.94 | $11.78 |
| Resistance Level | $10.22 | $12.51 |
| Average True Range (ATR) | 0.14 | 0.52 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 8.70 | 96.68 |
Price Performance
Historical ComparisonAbout NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.